The Australian CRO
With A Personalised Approach To Your Project
Where Biotech Innovation Meets Expert Clinical Trial Support

About Us
Alithia Life Sciences is a proudly Australian-owned, full-service Contract Research Organisation (CRO) partnering with pharmaceutical, biotechnology, and medical device companies, as well as institutional research groups, to deliver high-quality clinical development programs across Australia and globally.
Our team members have an average of 15+ years industry experience, providing deep expertise across a broad range of therapeutic areas including, first in human studies (FIH), neurology, devices, endocrinology, oncology, gastroenterology, rare and paediatric diseases and vaccines.
We work seamlessly across commercial, biotechnology and academic environments, supporting clinical programs from Phase I through Phase III with flexible, personalised solutions designed to meet the strategic and operational needs of each project.
From early-stage concept through to FDA approval, the Alithia team has successfully contributed to the successful development of innovative therapies. Our partners trust us to navigate every stage of the clinical development pathway with scientific rigour, operational excellence, and a commitment to advancing human health.
What We Do
Alithia connects your study with the right sites through rigorous feasibility and well-established investigator networks, setting a strong foundation from the outset. From efficient start-up to proactive monitoring and seamless close-out, we manage every stage to safeguard data quality and keep your trial on track.
Alithia provides dedicated project leadership that aligns strategy, timelines and resources, ensuring your study is delivered with clarity and control at every stage. With experienced oversight and proactive risk management, we integrate effortlessly with your organisation to drive efficient, compliant and predictable outcomes.
Alithia provides Australian local directorship to meet regulatory requirements and enable overseas sponsors to conduct clinical trials in Australia with confidence. This includes support for establishing the appropriate structure to access Australian R&D Tax Incentive benefits, alongside clear governance and experienced local oversight.
Along with our trusted Regulatory partners, Alithia offers strategic regulatory support across pharmaceuticals and medical devices, helping you define clear, defensible pathways from early development through to approval and lifecycle management. By combining deep regulatory expertise with critical evaluation of scientific data and proactive engagement with agencies, we help de-risk submissions and strengthen the quality and credibility of your development strategy.
Alithia delivers experienced medical monitoring through a network of actively practising physicians with current clinical and therapeutic expertise, ensuring all aspects of your study are overseen with up-to-date medical insight and strong focus on participant safety and data integrity. Acting as a proactive clinical partner, we review emerging safety signals, support site queries, and ensure timely interpretation and reporting of adverse events to maintain the scientific and regulatory robustness of your trial.
Along with our trusted medical writing partners, Alithia produces high-quality medical writing that converts complex clinical and scientific information into clear, submission-focused documentation to support robust decision-making and regulatory progression. Working in close partnership with your clinical and functional teams, we produce precise protocols, investigator materials and clinical study reports aligned to global requirements, with a strong emphasis on consistency, clarity and scientific integrity.
Alithia provides comprehensive pharmacovigilance services that ensure continuous monitoring, evaluation and reporting of safety data across your clinical and post-market programmes. Through proactive signal detection and rigorous regulatory compliance, we help safeguard patient wellbeing while strengthening the integrity and credibility of your product safety profile.
Alithia brings together expertise in data management and biostatistics to ensure your clinical trial data is designed for integrity, consistency and regulatory confidence from the outset. Through thoughtful study design, rigorous statistical planning and high-quality analysis, we work with our trusted network of Biometrics partners to generate outputs that stand up to regulatory scrutiny and support clear, defensible decision-making across your development programme.
Alithia offers end-to-end vendor management across clinical laboratories, Phase I units, recruitment partners, R&D tax specialists and IP advisers , and various other services providers, to ensure every external partner is aligned and accountable throughout your study. Through proactive coordination, clear communication and experienced oversight, we streamline vendor interactions to reduce complexity and fragmentation, mitigate risk and maintain momentum across your clinical programme.
Alithia delivers dedicated clinical trial liaison support to ensure clear, consistent communication across study sites, sponsors and operational teams throughout your clinical programme. By maintaining close coordination between all stakeholders, we help resolve issues efficiently, strengthen site engagement and support the smooth execution of multi-site and multi-region studies.
Alithia provides expert consulting to support informed decision-making across your clinical development pipeline, from early programme design through to operational strategy and study optimisation. By combining deep industry insight with practical trial experience, we help you evaluate options, mitigate risk and build clear, confident pathways from development planning through to execution.
Alithia provides quality assurance that is embedded across every stage of your clinical programmes, ensuring compliance, consistency and data integrity are maintained from start to finish. Through independent oversight, systematic review and internal auditing, we help strengthen operational processes and identify opportunities to enhance performance and regulatory readiness.

Our Vision And Mission

Alithia works in partnership with clients to deliver projects efficiently and successfully, while adding value to their programs and supporting the ongoing advancement of human health and wellbeing.
We combine agility and flexibility to respond quickly to the dynamic demands of clinical development, delivering projects with speed, quality, and operational excellence.
At all times, our team commits to:
- Working with our clients to deliver efficient accomplishment of their projects
- Adding value to their programs and,
- To ultimately enable improvement of human health and wellbeing.
Why Australia?
Australia has emerged as a premier destination for cutting-edge clinical research, offering a uniquely efficient and innovation-friendly environment for early-phase trials. Key advantages include:
- No IND or GMP manufacturing required for early-phase trials
- Rapid start-up timelines from protocol to first patient (2-3 months on average)
- Up to 43.5% R&D cash tax incentive
- Globally accepted data (FDA, EMA)
- Centralised Site Contracts to reduce contracting delays
- Diverse patients & world-class infrastructure

Meet Our Leaders

A/PROF TINA SOULIS
Founder and Director
A/Prof Tina Soulis has over 30 years of working in the healthcare (pharmaceuticals and devices), biotechnology, academic research, clinical research and management sectors in senior roles including: CEO of a Contract Research Organisation, Director of a successful ASX200 company, VP of Clinical Strategy and Development with an innovative biotechnology company and now, Founder and Director of her own full-service capability clinical CRO.
A dynamic and strategic leader, Tina has an extensive network of stakeholders all over the world and experience in many therapeutic areas across all phases on development. Tina is one of the few professionals in Australia to have taken a product from concept to FDA approval.
MS SAMANTHA GEORGE
Director of Clinical Operations
A senior executive with over 28 years of experience in research and development, biotechnology and clinical trials sectors. Specialised in building trusted teams and stakeholder relationships, with expertise in developing structure, systems and processes for emerging and expanding organisations.
MS JOVANA MILOSEVIC
Chief Commercial Officer
Jovana is an experienced clinical research executive with 16 years of leadership experience spanning CRO management, clinical operations, business development, and key account management, across leading global organisations. Her expertise extends across a broad range of therapeutic areas including C> and radiopharmaceuticals, with extensive experience in early phase research.
Jovana’s strategic approach, operational excellence, and deep cross-functional experience position her as a trusted leader in the clinical research and medical technology landscape.
Testimonials
Upcoming Events
Connect with us at major industry events across Australia and beyond to explore new ideas, partnerships, and possibilities.
UK–AUSTRALIA CLINICAL TRIALS INITIATIVE SESSION
Australian High Commission, United Kingdom
Australia House
London, UK
May 11, 2026, 17:30 – 19:30
Learn more and register here
AUSMEDTECH
Crown Towers
Perth, Australia
May 19 to 21, 2026
Learn more and register here
BIO 2026
San Diego Convention Center
San Diego, USA
June 22 to 25, 2026
Learn more and register here


Contact Us
Talk to us about how we can support achievement of your project goals.
Alithia Life Sciences: Overview | LinkedIn










